Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection

9 Aug 2013

Abstract excerpt

INTRODUCTION: Chronic Hepatitis C virus (HCV) infection is a major pandemic. The current standard of care includes peginterferon and ribavirin plus one of two protease inhibitors, boceprevir and telaprevir, for Genotype 1 patients and peginterferon and ribavirin for all other genotypes. The treatment landscape is rapidly evolving as a number of direct-acting antivirals (DAA) are being developed in clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis C virus research
Share to HIV/AIDS drug development and treatment
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23931586
DOI: 10.1517/13543784.2013.826189

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infectionPMID 23931586Read ↗

Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.Semantic proximity Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.Semantic proximity Read ↗

Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect.Semantic proximity Read ↗

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapySemantic proximity Read ↗

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.Semantic proximity Read ↗

Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.Semantic proximity Read ↗

The safety of daclatasvir for the treatment of hepatitis C.Semantic proximity Read ↗

Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.